Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $63.6M | $8.57M | $129M | $121M |
| Revenue growth | — | — | — | — | — | — | — | -86.5% | 1404.0% | -6.3% |
| Operating income | -$81.2M | -$122M | -$237M | -$296M | -$309M | -$340M | -$281M | -$276M | -$83.4M | $35.9M |
| Operating margin | — | — | — | — | — | — | -441.2% | -3219.5% | -64.7% | 29.7% |
| Net income | -$79.0M | -$119M | -$231M | -$291M | -$307M | -$340M | -$228M | -$276M | -$85.4M | $32.7M |
| Net margin | — | — | — | — | — | — | -359.1% | -3220.9% | -66.2% | 27.1% |
| EPS (diluted) | -$2.75 | -$4.00 | -$5.27 | -$5.67 | -$4.15 | -$3.63 | -$2.24 | -$65.19 | -$11.41 | $2.57 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$60.0M | -$87.5M | -$180M | -$236M | -$181M | -$221M | -$270M | -$193M | -$68.7M | -$50.9M |
| Capital expenditures | $3.02M | $20.2M | $35.9M | $5.73M | $4.51M | $10.6M | $4.19M | $1.22M | $246K | $0.00 |
| Free cash flow | -$63.0M | -$108M | -$216M | -$241M | -$185M | -$231M | -$275M | -$194M | -$69.0M | -$50.9M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $48.0M | $79.2M | $60.7M | $74.3M | $200M | $106M | $92.9M | $25.8M | $25.0M | $8.48M |
| Total assets | $264M | $218M | $392M | $343M | $588M | $468M | $376M | $166M | $109M | $20.2M |
| Total liabilities | $10.2M | $39.9M | $53.0M | $52.2M | $126M | $189M | $250M | $265M | $206M | $58.7M |
| Shareholders' equity | $254M | $178M | $339M | $291M | $462M | $280M | $127M | $99.2M | -$97.3M | -$38.5M |
| Retained earnings | -$177M | -$297M | -$527M | -$818M | -$1.12B | -$1.46B | -$1.69B | -$1.97B | -$2.05B | -$2.02B |
| Shares (wtd avg diluted) | 28.9M | 30.7M | 46.0M | 56.8M | 74.0M | 93.7M | 102M | 4.24M | 7.49M | 12.7M |
Every figure is extracted from Atara Biotherapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.